Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Adlyxin (DSC)
Synonyms :
lixisenatide
Class :
Glucagon-like Peptide-1 Agonist, Antidiabetics
Dosage Forms & StrengthsÂ
Subcutaneous injectableÂ
20 mcg/0.2 mLÂ
Indicated for Diabetes Mellitus Type 2
Initial dose: 10 mcg subcutaneously every day for 14 days
Maintenance dose: Enhance the dose to 20 mcg every day from Day-15
It is used to improve glycemic control as with addition to diet and regular exercise
Safety and efficacy not establishedÂ
Refer to adult doseÂ
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
lixisenatide: they may decrease the therapeutic effect of hormonal contraceptives
lixisenatide: they may decrease the therapeutic effect of hormonal contraceptives
lixisenatide: they may decrease the therapeutic effect of hormonal contraceptives
lixisenatide: they may decrease the therapeutic effect of hormonal contraceptives
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with meglitinides
may have an increased hypoglycemic effect when combined with meglitinides
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect of Sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
It may diminish the effect when combined with lixisenatide by inhibiting gastrointestinal absorption
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
It may diminish the effect when combined with lixisenatide by inhibiting gastrointestinal absorption
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
When halometasone is used together with lixisenatide, this leads to elevated risk or seriousness of hyperglycemia
When lixisenatide is used together with diazoxide, this leads to reduction in therapeutic effectiveness of lixisenatide
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with lixisenatide, this leads to elevated hyperglycemia risk
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may decrease the therapeutic effect when combined with glucagon and its analogs
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
It may diminish the effect when combined with lixisenatide by inhibiting gastrointestinal absorption
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
It may diminish the effect when combined with lixisenatide by inhibiting gastrointestinal absorption
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
hormonal contraceptives decrease the efficacy of lixisenatide
Actions and Spectrum:Â
lixisenatide is a medication used in the treatment of type 2 diabetes mellitus. It belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 agonists) and acts by mimicking the action of the endogenous hormone glucagon-like peptide-1 (GLP-1). Â
Action:Â
Spectrum:Â
Frequency not definedÂ
Low blood sugarÂ
DizzinessÂ
NauseaÂ
VomitingÂ
DiarrheaÂ
HeadacheÂ
Black Box Warning:Â
NoneÂ
Contraindication/Caution:Â
ContraindicationÂ
lixisenatide has certain contraindications, which are specific situations or conditions in which medication use is not recommended. Â
CautionÂ
While lixisenatide is generally safe and well-tolerated, there are some cautions and precautions to be aware of when using this medication. Â
Pregnancy consideration:Â Â
AU TGA pregnancy category: B3
US FDA pregnancy category: Not assignedÂ
Lactation:  Â
Excreted into human milk: Not known.Â
Pregnancy category:Â
Pharmacology:Â
lixisenatide is a GLP-1 receptor agonist that exerts its pharmacological effects by mimicking the action of endogenous glucagon-like peptide-1 (GLP-1). lixisenatide activates GLP-1 receptors upon subcutaneous injection, leading to multiple physiological actions. It enhances glucose-dependent insulin secretion from pancreatic beta cells, reducing blood glucose levels.
lixisenatide also suppresses glucagon release from pancreatic alpha cells, further contributing to glycemic control. Additionally, it slows gastric emptying, resulting in reduced postprandial glucose excursions. lixisenatide may also promote satiety and reduce appetite, potentially leading to weight loss. These mechanisms collectively help improve glycemic control in individuals with type 2 diabetes mellitus.Â
Pharmacodynamics:Â
Mechanism of action: lixisenatide exerts its pharmacological effects through its mechanism of action as a glucagon-like peptide-1 receptor agonist. Â
Pharmacokinetics:Â
AbsorptionÂ
lixisenatide is administered via subcutaneous injection, allowing direct absorption into the bloodstream. After injection, lixisenatide is rapidly absorbed, reaching peak plasma concentrations within 1-3 hours. The absolute bioavailability of lixisenatide following subcutaneous administration is approximately 40%.Â
DistributionÂ
In terms of distribution, lixisenatide has a relatively small volume of distribution, indicating limited extravascular distribution. It binds extensively to plasma proteins, primarily albumin. The protein binding is concentration-independent, with approximately 98% of lixisenatide bound to plasma proteins.Â
MetabolismÂ
Metabolism of lixisenatide primarily occurs via enzymatic degradation. The main metabolic pathway involves proteolytic cleavage by dipeptidyl peptidase-4 (DPP-4), resulting in the formation of metabolites with minimal biological activity. These metabolites are further degraded to smaller peptides and amino acids.Â
Elimination and ExcretionÂ
lixisenatide is eliminated mainly through renal excretion. After administration, approximately 15-20% of the dose is excreted unchanged in the urine. The elimination half-life of lixisenatide is relatively short, ranging from 2-4 hours, indicating rapid clearance from the body.Â
Administration:Â
Subcutaneous administrationÂ
lixisenatide is typically administered as a subcutaneous injection.Â
Injection Sites:Â Â
Preparing the Injection:Â Â
Administration Steps:Â Â
Patient information leafletÂ
Generic Name: lixisenatideÂ
Pronounced: [ LIX-i-SEN-a-tide ]Â
Why do we use lixisenatide?Â
lixisenatide is primarily used for the treatment of type 2 diabetes mellitus. It is prescribed to help control blood sugar levels in individuals with this condition. Â